SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic…
** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the…
** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the…
November 18, 2024 11:15 ET | Source: BridgeBio Pharma, Inc. - Acoramidis demonstrated the earliest known time to separation in…
Los Angeles, CA, Nov. 08, 2024 (GLOBE NEWSWIRE) -- With the announcement of Donald Trump’s victory in the U.S. presidential…
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the…